Supratik Basu

MAIA frailty subgroup analysis: Long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin et autres

© [year of publication]The Authors. Published by Nature. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: [DOI/weblink]

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Thierry Façon, Shaji Kumar, Robert Z. Orlowski, Nizar J. Bahlis et autres

In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. …

fr, us, ca, de, gb, nl, se, dk, au (code pays fourni par la source)

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

Sonja Zweegman, Saad Z. Usmani, Vânia Hungria, Nizar J. Bahlis et autres

Daratumumab, lenalidomide, and dexamethasone (DRd) is approved to treat transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) based on the phase 3 MAIA trial [ 1 , 2 , 3 ]. Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) is approved to treat patients …

nl, us, br, ca, cz, es, gb, il, jp, fr, pl (code pays fourni par la source)

POSTER: MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis et autres

us, fr, br, ca, cz, es, gb, il, jp, pl, tr, nl (code pays fourni par la source)

MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis et autres

us, fr, br, ca, cz, es, gb, il, jp, pl, tr, nl (code pays fourni par la source)

Extended rank regression for all ordinal data

Peter Hoff, Supratik Basu

The accuracy of inference from a regression model depends largely on how well the model represents the relationship between the mean and variance of the outcomes. As this relationship is rarely of direct interest, it is natural to treat it as a …

Extended rank regression for all ordinal data

Peter Hoff, Supratik Basu

The accuracy of inference from a regression model depends largely on how well the model represents the relationship between the mean and variance of the outcomes. As this relationship is rarely of direct interest, it is natural to treat it as a …

us (code pays fourni par la source)

SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS

Elizabeth Knight, A. Krishnamoorthi, Berrin Balik, Sulgi Byun et autres

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma-cell disorder characterised by the presence of a monoclonal protein without end-organ damage and is the earliest clinically detectable precursor to multiple myeloma (MM) [ 1 ]. MGUS is common in ageing populations, …

gb, tr (code pays fourni par la source)

Universally Optimal Robustness-Efficiency Tradeoffs for a General Class of Minimum Divergence Estimators

Subhrajyoty Roy, Supratik Basu, Ashis Ghosh, Ayanendranath Basu

Balancing the efficiency of an estimator under ideal conditions against its robustness under contamination remains a central challenge in robust statistics. While minimum divergence methods offer a flexible alternative to traditional M-estimation, choosing the appropriate discrepancy measure has historically relied on heuristic …

Universally Optimal Robustness-Efficiency Tradeoffs for a General Class of Minimum Divergence Estimators

Subhrajyoty Roy, Supratik Basu, Ashis Ghosh, Ayanendranath Basu

Balancing the efficiency of an estimator under ideal conditions against its robustness under contamination remains a central challenge in robust statistics. While minimum divergence methods offer a flexible alternative to traditional M-estimation, choosing the appropriate discrepancy measure has historically relied on heuristic …

us, in (code pays fourni par la source)

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS

Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis et autres

ABSTRACT: In the phase 3 CEPHEUS study, D-VRd (daratumumab/bortezomib/lenalidomide/dexamethasone) increased overall minimal residual disease (MRD)-negativity rates vs VRd in patients who were transplant ineligible/deferred with newly diagnosed multiple myeloma (NDMM). We present an expanded MRD analysis of CEPHEUS. Patients who were transplant-ineligible …

nl, fr, br, ca, us, cz, es, gb, il, jp, pl, tr (code pays fourni par la source)

Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.

Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar Jacques J. Bahlis et autres

7513 Background: The phase 3 CEPHEUS study established that DVRd improved overall minimal residual disease (MRD)-negativity (neg) rates and progression-free survival (PFS) vs VRd in pts with TIE or transplant-deferred (TD) NDMM. The first analysis of the DVRd TIE subpopulation at a …

us, fr, br, ca, cz, es, gb, il, jp, pl, tr, nl (code pays fourni par la source)